FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.
What happened
FDA inspected the company's drug manufacturing facility in Henderson, Nevada, from February 18 to 20, 2025. Investigators found the quality control unit was not doing its job: finished drug products were not tested before release, there was no adequate stability program, and batch records were incomplete. The company also did not test incoming ingredients to confirm identity and relied on suppliers' certificates of analysis without verifying them. FDA said it received no response to the Form FDA 483 (the list of inspection observations); the firm told FDA it does not intend to make OTC drugs and has discontinued its drug registration.
What FDA found
The quality unit lacked the authority and resources to oversee drug manufacturing and make sure products met specifications.
21 CFR 211.22Finished drug products were not adequately tested before release and distribution.
21 CFR 211.165(a) and (b)The company had no adequate ongoing stability program to show products stay good through their shelf life.
21 CFR 211.166(a)Batch production and control records did not fully document each significant manufacturing step for every batch.
21 CFR 211.188The company did not test each incoming lot of ingredients for identity and did not validate suppliers' test results.
21 CFR 211.84(d)(1) and 211.84(d)(2)There was no program to qualify raw material suppliers, even though some ingredients carry a risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination, which has caused fatal poisonings.
21 CFR 211.84(d)(2)
What FDA wants
FDA asks the company to reply in writing within 15 working days describing what it has done to fix the violations and prevent recurrence, including DEG and EG test results within 30 calendar days. FDA also asks the firm to say whether it will resume drug manufacturing and to notify the agency before doing so.
Who should pay attention
- brands that buy finished OTC drug products from this contract manufacturer
- retailers and distributors selling store-brand OTC drugs made here
- companies buying glycerin or other high-risk ingredients from the same suppliers
This is a summary. Read the original letter on fda.gov.